Meisi Yan

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma”.

Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma

Journal of Hepatology(2020)10.1016/j.jhep.2020.09.030

N/A

0DataRank · unranked

32 citations

Zhengyu Zha, Chenhao Zhou, Yeh Chen, Weiya Xia, Ying‐Nai Wang +14 more

TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

Journal of Clinical Investigation(2021)10.1172/jci139434

N/A

0DataRank · unranked

314 citations

Seung-Oe Lim, Meisi Yan, Jennifer L. Hsu, Jun Yao, Yongkun Wei +12 more

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation

Nature Communications(2021)10.1038/s41467-021-23075-2

N/A

0DataRank · unranked

31 citations

Ying‐Nai Wang, Wenhao Yang, Weiya Xia, Yongkun Wei, Li-Chuan Chan +25 more

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

Signal Transduction and Targeted Therapy(2025)10.1038/s41392-025-02206-x

N/A

0DataRank · unranked

6 citations

Chunxiao Liu, Meisi Yan, Cong Chen, Yu Cheng, Yaohui Chen +20 more